Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008942 | 0.85 | POLB (0.43) | MAPTCYP1A2CYP2C19HDAC1HDAC2 | |
| SCHEMBL2003592 | 0.84 | ATM (0.41) | ANPEPMAPTALDH1A1TP53LMNA | |
| SCHEMBL2009219 | 0.83 | THRB (0.39) | ANPEPPTGDR2MAPTALDH1A1TP53 | |
| SCHEMBL2009801 | 0.82 | MAPT (0.38) | ANPEPPTGDR2MAPTALDH1A1TP53 | |
| SCHEMBL2005269 | 0.82 | CHRM5 (0.40) | PTGDR2MAPTCYP2C19ALDH1A1TP53 | |
| SCHEMBL2009399 | 0.81 | ALDH1A1 (0.36) | ANPEPPTGDR2MAPTHDAC1ALDH1A1 | |
| SCHEMBL2824115 | 0.80 | ANPEP (0.48) | ANPEPPTGDR2HDAC1HDAC2ALDH1A1 | |
| SCHEMBL2006817 | 0.80 | ALDH1A1 (0.36) | MAPTCYP2C19ALDH1A1TP53LMNA | |
| SCHEMBL7834757 | 0.75 | PARK7 (0.44) | ANPEPPTGDR2MAPTCYP1A2CYP2C19 | |
| SCHEMBL2010777 | 0.72 | L3MBTL1 (0.36) | CYP1A2CYP2C19TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620399-B1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | claimed |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-02-22 | — | — | US | claimed |
| US-7964593-B2 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2011-06-21 | — | — | US | disclosed |
| EP-1620399-B1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100069375-A1 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2010-03-18 | — | — | US | disclosed |
| US-7645887-B2 | 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide | UCB PHARMA, S.A. (BE) | 2010-01-12 | — | — | US | disclosed |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069375-A1 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses | AANAT, TPH2, CYP1A2 | ANPEP 2038/4885PTGDR2 662/4885MAPT 387/4885 |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | AANAT, TPH2, CYP1A2 | ANPEP 2038/4885PTGDR2 662/4885MAPT 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.